Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity.

Abstract

Chronic pain may result from hyperexcitability following activation of spinal NMDA receptors. A naturally-derived mammalian peptide, histogranin, may possess NMDA antagonist activity. This study explored the possibility that stable analog [Ser1]Histogranin (SHG) could reduce chronic pain. Neuropathic pain was induced using the chronic constriction injury model (CCI). Intrathecal injection of SHG markedly attenuated the hyperalgesia and allodynia resulting from CCI, nearly normalizing responses. These results suggest that the natural peptide histogranin may be a novel adjunct in neuropathic pain management.

• Authors: J B Siegan, A T Hama, J Sagen
• Journal: Brain research (Brain Res) Vol. 755 Issue 2 Pg. 331-4 (May 02 1997) ISSN: 0006-8993 [Print] Netherlands
• PMID: 9175901 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Excitatory Amino Acid Antagonists
• Proteins
• Receptors, N-Methyl-D-Aspartate
• histogranin

Topics

• Animals
• Depression, Chemical
• Excitatory Amino Acid Antagonists (therapeutic use)
• Hyperalgesia (drug therapy)
• Injections, Spinal
• Male
• Neuralgia (drug therapy)
• Peripheral Nerve Injuries
• Proteins (therapeutic use)
• Rats
• Rats, Sprague-Dawley
• Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)